https://www.live-feeds.com/feed/retatrutide-beats-ozempic-on-weight-loss-blood-sugar-control-study-saysContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/retatrutide-beats-ozempic-on-weight-loss-blood-sugar-control-study-sayshttps://www.live-feeds.com/feed/retatrutide-beats-ozempic-on-weight-loss-blood-sugar-control-study-says#u166719Sun, 01 Nov 2026 04:21:15 +0000Eli Lilly's experimental drug retatrutide showed greater weight loss and improved blood sugar control compared to Novo's Ozempic in a head-to-head trial. Retatrutide helped patients lose more than twice as much weight as Ozempic's highest approved dose. The study's results support a regulatory application expected in the first quarter of 2027.Why it mattersThe study compared retatrutide, a triple-G drug, with Ozempic, a popular diabetes medication also used for weight loss. The results have significant implications for the obesity and diabetes treatment markets. Lilly'